IntegraGen SA, a company specializing in the decoding of the human genome and performing interpretable genomic tests for academic and private laboratories and a developer of diagnostic tools in oncology, and Laboratoire CERBA, have signed a licensing agreement allowing Laboratoire CERBA to develop and provide to prescribing clinicians a test based on IntegraGen’s proprietary miR-31-3p biomarker.
According to agreement, Laboratoire CERBA will develop this test to complement its existing portfolio and further enable physicians to proactively identify metastatic colorectal cancer patients who will have increased benefit from treatment with anti-EGFR therapy.
The company did not disclose financial details and terms of the agreement.
“Laboratoire CERBA has a longstanding history of providing innovative & clinically relevant tests to clinicians and patients, and it is a natural expansion of our testing portfolio to include miR-31-3p to our portfolio of tests. With this licensing agreement we remain at the forefront of precision medicine and are able to provide oncologists genomic information that will allow them to choose the optimal therapy for patients with metastatic colorectal cancer, a disease that affects more than 170,000 patients in the EU,” said Sylvie Cado, CEO of Laboratoire CERBA.
Bernard Courtieu, IntegraGen’s CEO said, “With the launch of our first proprietary test in Europe, it also represents the culmination of more than five years of research and development efforts, from the early stages of biomarker discovery to the availability of a miR-31-3p expression test for oncologists and patients.”